paediatrics Brussels 17

Dose Reduction in Low-Risk Rhabdomyosarcoma

• Children’s Oncology Group D9602 Study • Eligibility:

1. nonmetastatic rhabdomyosarcoma in a favorable site (orbit, non-parameningeal head and neck, nonprostate/nonbladder genitourinary, biliary tract) 2. nonmetastatic rhabdomyosarcoma in an unfavorable site with gross total resection of all tumor at diagnosis (Group I or II) 3. initially alveolar subtype included (1997) but later excluded (1999)

Breneman J et al. Int J Radiat Oncol Biol Phys 2012; 83:720-6